GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial
02 Mayo 2019 - 11:59AM
Noticias Dow Jones
By Adria Calatayud
GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said
Thursday that their Trelegy Ellipta inhaler, which treats patients
living with uncontrolled asthma, met the primary endpoint in a
phase 3 study.
The pharmaceutical companies said the study showed a
statistically significant improvement in lung function at 24 weeks
of once-daily treatment with Trelegy Ellipta compared with other
medication.
However, the drug didn't achieve a statistically significant
reduction in the annualized rate of asthma exacerbations, which was
the secondary endpoint of the trial, the companies said.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
May 02, 2019 12:44 ET (16:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024